# BMT CTN 1102 (NCT02016781)

> Allo vs Hypomethylating/Best Supportive Care in MDS (BMTCTN1102)

No report yet. It can be ordered.

- Drugs tested: none (the trial tests no drug)
- Indication: intermediate-2 and high-risk myelodysplastic syndrome

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02016781
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Medical College of Wisconsin
- Conditions: MDS
- Interventions: Allogeneic Hematopoietic Cell Transplant; Hypomethylating Therapy / Best Supportive Care
- Enrollment: 384
- Primary outcome: Percentage of Participants With Overall Survival (OS)

## Indexed commentary on BMT CTN 1102 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 10 posts on X
- 5 podcast episodes
- 2 YouTube videos

## Order

Standard, $1,250 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=bmt-ctn-1102-nct02016781

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02016781", "email": "<work email>"}; the inbox owner confirms by the emailed link.